- Veterans Often Reluctant to Admit Struggles With Sleep, Addictions
- Premature Birth Tied to Higher Risk for ADHD
- If a Child’s Grades Falter, Consider Hearing Loss
- Dog Contracts Monkeypox From Owners, Prompting Change to CDC Guidance
- U.S. Nursing Homes Are Understaffed, But Minority Communities Have It Worst
- Nerve Block Plus Lidocaine Clears Psoriasis in Small Study
- Scotland Becomes 1st Country to Provide Free Period Products
- U.K. Is First Country to Approve Moderna’s Omicron-Targeted COVID Vaccine
- Monkeypox May Get New Name to Curb Stigma
- Heat, Smoke & the Heart: Wildfires Cause Cardiac Crises
Vimizim Approved for Rare Childhood Disorder

Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.
The disorder is caused by a missing metabolic enzyme that leads to problems with bone development, growth and movement, the agency said in a news release. It affects about 800 people in the United States.
Vimizim replaces the missing enzyme, known as GALNS. The drug’s safety and effectiveness were established in clinical trials involving 176 people, ranging in age from 5 to 57. The most common side effects included fever, vomiting, headache, nausea, abdominal pain, chills and fatigue, the FDA said.
The drug’s safety and effectiveness weren’t evaluated in children under age 5 years, the agency added. Vimizim’s label will include a boxed warning to include the risk of anaphylaxis, an allergic-like reaction that could be life threatening.
Vimizim was the first drug granted a Rare Pediatric Disease Priority Review Voucher, an FDA effort to encourage development of new treatments for rare childhood diseases.
The drug is marketed by BioMarin Pharmaceuticals, based in Novoto, Calif.
More information
The FDA has more about this approval.
Source: HealthDay